Articles related to OBESITY/WEIGHT MANAGEMENT

Bariatric surgery volumes peaked in 2022 and have fallen since, with sleeve gastrectomy losing ground and Roux-en-Y conversions climbing as GLP-1 prescriptions expand.

A systematic review of 27 studies found behavioral sleep interventions — particularly CBT-I and sleep hygiene — reduced BMI and body weight in adults with poor sleep health, with the largest effects among patients with obesity.

The FDA announced on April 30, 2026 it is considering removing GLP-1 receptor agonists from the 503B bulks list, with public comment open through the end of June 2026.

A clinical review outlines how OBGYNs can integrate GLP-1 receptor agonist therapy into obesity care for women of reproductive age, with attention to fertility, contraception, and adherence.

Boehringer Ingelheim’s SYNCHRONIZE-1 phase 3 trial reported 16.6% average body weight reduction with survodutide, a dual GLP-1/glucagon receptor agonist, over 76 weeks in adults without type 2 diabetes.

Children labeled metabolically healthy at obesity treatment initiation reached an 18-fold higher type 2 diabetes incidence by age 30 than general population peers in a 42,911-patient Swedish cohort.